Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals

Hepatobiliary and Pancreatic Diseases International

Volumn 16, Issue 5, 2017, Pages 470-479

  Huang, Yan ^a   Li, Ming Hui ^b   Hou, Min ^a   Xie, Yao ^b  

^a Shanghai Roche Pharmaceuticals Ltd   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

chronic hepatitis C; direct acting antivirals; hepatitis C virus; peginterferon alfa 2a; ribavirin

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; ELBASVIR PLUS GRAZOPREVIR; HEMOGLOBIN; INTERLEUKIN 28B; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; THYROID HORMONE; UNCLASSIFIED DRUG; ALPHA INTERFERON; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

AGGRESSION; ALL CAUSE MORTALITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS C; DEPRESSION; DRUG MECHANISM; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; HEPATITIS B; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MENTAL DISEASE; MIXED INFECTION; MOOD CHANGE; NEUTROPENIA; RETREATMENT; REVIEW; SEVERE RENAL IMPAIRMENT; SIDE EFFECT; SUICIDAL BEHAVIOR; SUSTAINED VIROLOGIC RESPONSE; VIRUS REACTIVATION; VOLUME OF DISTRIBUTION; CHRONIC KIDNEY FAILURE; METABOLISM;

ANTIVIRAL AGENTS; COINFECTION; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS;

EID: 85030725376     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(17)60044-4     Document Type: Review

References (79)

1. WHO Guidelines Approved by the Guidelines Review Committee, Guidelines for the screening, care and treatment of persons with hepatitis C infection, 2014, World Health Organization, Geneva.
2. Yu, ML, Chuang, WL, New treatments for HCV: perspective from Asia. Clin Liver Dis 5 (2015), 17–21.
3. Omata, M, Kanda, T, Wei, L, Yu, ML, Chuang, WL, Ibrahim, A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 10 (2016), 702–726.
4. European Association for the Study of the Liver, EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
5. Feld, JJ, Hoofnagle, JH, Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005), 967–972.
6. Brassard, DL, Grace, MJ, Bordens, RW, Interferon-alpha as an immunotherapeutic protein. J Leukoc Biol 71 (2002), 565–581.
7. Sadler, AJ, Williams, BR, Interferon-inducible antiviral effectors. Nat Rev Immunol 8 (2008), 559–568.
8. Parker, BS, Rautela, J, Hertzog, PJ, Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16 (2016), 131–144.
9. Chang, XM, Chang, Y, Jia, A, Effects of interferon-alpha on expression of hepatic stellate cell and transforming growth factor-beta1 and alpha-smooth muscle actin in rats with hepatic fibrosis. World J Gastroenterol 11 (2005), 2634–2636.
10. Wang, L, Tang, ZY, Qin, LX, Wu, XF, Sun, HC, Xue, Q, et al. Highdose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 32 (2000), 43–48.
11. Kusano, H, Akiba, J, Ogasawara, S, Sanada, S, Yasumoto, M, Nakayama, M, et al. Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One, 8, 2013, e83195.
12. Breitenstein, S, Dimitroulis, D, Petrowsky, H, Puhan, MA, Müllhaupt, B, Clavien, PA, Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 96 (2009), 975–981.
13. Shen, YC, Hsu, C, Chen, LT, Cheng, CC, Hu, FC, Cheng, AL, Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 52 (2010), 889–894.
14. Miyake, Y, Takaki, A, Iwasaki, Y, Yamamoto, K, Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 17 (2010), 287–292.
15. Liang, KH, Hsu, CW, Chang, ML, Chen, YC, Lai, MW, Yeh, CT, Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis 213 (2016), 966–974.
16. Hiramatsu, N, Oze, T, Takehara, T, Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based antiviral therapy. Hepatol Res 45 (2015), 152–161.
17. Zeuzem, S, Welsch, C, Herrmann, E, Pharmacokinetics of peginterferons. Semin Liver Dis 23 (2003), 23–28.
18. Perry, CM, Jarvis, B, Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C. Drugs 61 (2001), 2263–2288.
19. Awad, T, Thorlund, K, Hauser, G, Stimac, D, Mabrouk, M, Gluud, C, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology 51 (2010), 1176–1184.
20. Poordad, F, McCone, J Jr, Bacon, BR, Bruno, S, Manns, MP, Sulkowski, MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1195–1206.
21. Jacobson, IM, McHutchison, JG, Dusheiko, G, Di Bisceglie, AM, Reddy, KR, Bzowej, NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364 (2011), 2405–2416.
22. Lawitz, E, Mangia, A, Wyles, D, Rodriguez-Torres, M, Hassanein, T, Gordon, SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368 (2013), 1878–1887.
23. Fried, MW, Shiffman, ML, Reddy, KR, Smith, C, Marinos, G, Gonçales, FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002), 975–982.
24. Hadziyannis, SJ, Sette, H Jr, Morgan, TR, Balan, V, Diago, M, Marcellin, P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140 (2004), 346–355.
25. Chen, Y, Xu, HX, Wang, LJ, Liu, XX, Mahato, RI, Zhao, YR, Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin. Aliment Pharmacol Ther 36 (2012), 91–103.
26. Schreiber, J, Moreno, C, Garcia, BG, Louvet, A, Trepo, E, Henrion, J, et al. Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients. Aliment Pharmacol Ther 36 (2012), 353–362.
27. Rangnekar, AS, Fontana, RJ, Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients. Aliment Pharmacol Ther 36 (2012), 104–114.
28. Thomas, DL, Thio, CL, Martin, MP, Qi, Y, Ge, D, O'Huigin, C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461 (2009), 798–801.
29. Yu, ML, Chuang, WL, Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24 (2009), 336–345.
30. Yu, ML, Dai, CY, Huang, JF, Chiu, CF, Yang, YH, Hou, NJ, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 47 (2008), 1884–1893.
31. Yu, ML, Huang, CF, Huang, JF, Chang, NC, Yang, JF, Lin, ZY, et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53 (2011), 7–13.
32. D'Ambrosio, R, Aghemo, A, Rumi, MG, Ronchi, G, Donato, MF, Paradis, V, et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
33. George, SL, Bacon, BR, Brunt, EM, Mihindukulasuriya, KL, Hoffmann, J, Di Bisceglie, AM, Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 49 (2009), 729–738.
34. Bacon, BR, Gordon, SC, Lawitz, E, Marcellin, P, Vierling, JM, Zeuzem, S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364 (2011), 1207–1217.
35. Zeuzem, S, Andreone, P, Pol, S, Lawitz, E, Diago, M, Roberts, S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364 (2011), 2417–2428.
36. Jacobson, IM, Dore, GJ, Foster, GR, Fried, MW, Radu, M, Rafalsky, VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384 (2014), 403–413.
37. Foster, GR, Pianko, S, Brown, A, Forton, D, Nahass, RG, George, J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 149 (2015), 1462–1470.
38. Itakura, J, Kurosaki, M, Higuchi, M, Takada, H, Nakakuki, N, Itakura, Y, et al. Resistance-associated NS5A variants of hepatitis C virus are susceptible to interferon-based therapy. PLoS One, 10, 2015, e0138060.
39. McPhee, F, Suzuki, Y, Toyota, J, Karino, Y, Chayama, K, Kawakami, Y, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther 32 (2015), 637–649.
40. Sarrazin, C, The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64 (2016), 486–504.
41. Peiffer, KH, Sommer, L, Susser, S, Vermehren, J, Herrmann, E, Döring, M, et al. Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3. Hepatology 63 (2016), 63–73.
42. Lawitz, E, Matusow, G, DeJesus, E, Yoshida, EM, Felizarta, F, Ghalib, R, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64 (2016), 360–369.
43. Pol, S, Sulkowski, MS, Hassanein, T, Gane, EJ, Liu, L, Mo, H, et al. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology 62 (2015), 129–134.
44. Schwarz, KB, Mohan, P, Narkewicz, MR, Molleston, JP, Nash, SR, Hu, S, et al. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 43 (2006), 499–505.
45. Sokal, EM, Bourgois, A, Stéphenne, X, Silveira, T, Porta, G, Gardovska, D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 52 (2010), 827–831.
46. Schwarz, KB, Gonzalez-Peralta, RP, Murray, KF, Molleston, JP, Haber, BA, Jonas, MM, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 140 (2011), 450–458.e1.
47. Druyts, E, Thorlund, K, Wu, P, Kanters, S, Yaya, S, Cooper, CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 56 (2013), 961–967.
48. Schwarz, KB, Molleston, JP, Jonas, MM, Wen, J, Murray, KF, Rosenthal, P, et al. Durability of response in children treated with pegylated interferon alfa [corrected] 2a ± ribavirin for chronic hepatitis C. J Pediatr Gastroenterol Nutr 62 (2016), 93–96.
49. Balistreri, WF, Murray, KF, Rosenthal, P, Bansal, S, Lin, CH, Kersey, K, et al. The safety and effectiveness of ledipasvirsofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology, 2016 Dec 20.
50. Chen, X, Shang, J, Yang, R, Xie, Q, Gao, Z, Xu, X, et al. High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study. Zhonghua Gan Zang Bing Za Zhi 23 (2015), 412–417.
51. Rao, H, Yang, R, Shang, J, Xu, X, Chen, X, Dou, X, et al. The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients. Zhonghua Nei Ke Za Zhi 54 (2015), 699–704.
52. Shang, J, Xu, X, Chen, X, Gao, Z, Gong, G, Feng, Y, et al. Efficacy and related factors of pegylated interferon α-2a plus ribavirin therapy for chronic hepatitis C in non-responders. Chin J Clin Infect Dis 8 (2015), 232–237.
53. Hsu, CS, Chao, YC, Lin, HH, Chen, DS, Kao, JH, Systematic review: impact of interferon-based therapy on HCV-related hepatocellular carcinoma. Sci Rep, 5, 2015, 9954.
54. van der Meer, AJ, Veldt, BJ, Feld, JJ, Wedemeyer, H, Dufour, JF, Lammert, F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
55. Singal, AK, Freeman, DH Jr, Anand, BS, Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32 (2010), 851–858.
56. Hagihara, H, Nouso, K, Kobayashi, Y, Iwasaki, Y, Nakamura, S, Kuwaki, K, et al. Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Int J Clin Oncol 16 (2011), 210–220.
57. Conti, F, Buonfiglioli, F, Scuteri, A, Crespi, C, Bolondi, L, Caraceni, P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
58. Reig, M, Mariño, Z, Perelló, C, Iñarrairaegui, M, Ribeiro, A, Lens, S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65 (2016), 719–726.
59. Toyoda, H, Tada, T, Takaguchi, K, Senoh, T, Shimada, N, Hiraoka, A, et al. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. J Viral Hepat 24 (2017), 472–476.
60. Kozbial, K, Moser, S, Schwarzer, R, Laferl, H, Al-Zoairy, R, Stauber, R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 65 (2016), 856–858.
61. Serti, E, Chepa-Lotrea, X, Kim, YJ, Keane, M, Fryzek, N, Liang, TJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200.e2.
62. AASLD-IDSA, Recommendations for testing, managing, and treating hepatitis C 2016 [22 February 2017]. Available from: http://www.hcvguidelines.org.
63. Barril, G, Quiroga, JA, Sanz, P, Rodrìguez-Salvanés, F, Selgas, R, Carreño, V, Pegylated interferon-alpha2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialysers. Aliment Pharmacol Ther 20 (2004), 37–44.
64. Heathcote, J, Main, J, Treatment of hepatitis C. J Viral Hepat 12 (2005), 223–235.
65. Liu, CH, Liu, CJ, Huang, CF, Lin, JW, Dai, CY, Liang, CC, et al. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Gut 64 (2015), 303–311.
66. Liu, CH, Huang, CF, Liu, CJ, Dai, CY, Liang, CC, Huang, JF, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med 159 (2013), 729–738.
67. Liu, CH, Liang, CC, Liu, CJ, Lin, JW, Chen, SI, Hung, PH, et al. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C. Clin Infect Dis 51 (2010), 541–549.
68. Hsu, YH, Hung, PH, Muo, CH, Tsai, WC, Hsu, CC, Kao, CH, Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease: an 8-year nationwide cohort study in Taiwan. Medicine (Baltimore), 94, 2015, e2113.
69. Pharmaceuticals and Medical Devices Agency, Summary of investigation results. Ombitasvir hydrate/paritaprevir hydrate/ritonavir. Available from: http://www.pmda.go.jp/files/000212938.pdf, 2016.
70. Liu, CJ, Chen, PJ, Chen, DS, Dual chronic hepatitis B virus and hepatitis C virus infection. Hepatol Int 3 (2009), 517–525.
71. Konstantinou, D, Deutsch, M, The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management. Ann Gastroenterol 28 (2015), 221–228.
72. Liu, CJ, Chuang, WL, Lee, CM, Yu, ML, Lu, SN, Wu, SS, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 136 (2009), 496–504.e3.
73. Yeh, ML, Hung, CH, Huang, JF, Liu, CJ, Lee, CM, Dai, CY, et al. Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One, 6, 2011, e20752.
74. Yeh, ML, Hsieh, MY, Huang, CI, Huang, CF, Hsieh, MH, Liang, PC, et al. Personalized therapy of chronic hepatitis C and B dually infected patients with pegylated interferon plus ribavirin: a randomized study. Medicine (Baltimore), 94, 2015, e1837.
75. Yu, ML, Lee, CM, Chuang, WL, Lu, SN, Dai, CY, Huang, JF, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 202 (2010), 86–92.
76. Yu, ML, Lee, CM, Chen, CL, Chuang, WL, Lu, SN, Liu, CH, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology 57 (2013), 2135–2142.
77. Liu, CJ, Chu, YT, Shau, WY, Kuo, RN, Chen, PJ, Lai, MS, Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut 63 (2014), 506–514.
78. Administration UFaD, FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C 2016. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm522932.htm, 22 February 2017.
79. Collins, JM, Raphael, KL, Terry, C, Cartwright, EJ, Pillai, A, Anania, FA, et al. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis 61 (2015), 1304–1306.